Total Funding
67
53
Total FundingPost-IPO Secondary raised
Growth Score
-7 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
59633
DBV Technologies focuses on the development of innovative products for the diagnosis and treatment of food allergies.
- Daniel Tasse: Chief Executive OfficerPast Role: Ikaria, Chief Executive Officer
Pierre Benhamou: Co-Founder & CEO
About the Company
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy
that aims to activate the immune system of patients through the skin.
